139 related articles for article (PubMed ID: 22421928)
1. CCN3: a novel anti-fibrotic treatment in end-stage renal disease?
Leask A
J Cell Commun Signal; 2012 Jun; 6(2):115-6. PubMed ID: 22421928
[TBL] [Abstract][Full Text] [Related]
2. A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effects.
van Roeyen CR; Boor P; Borkham-Kamphorst E; Rong S; Kunter U; Martin IV; Kaitovic A; Fleckenstein S; Perbal B; Trautwein C; Weiskirchen R; Ostendorf T; Floege J
Am J Pathol; 2012 May; 180(5):1979-90. PubMed ID: 22538190
[TBL] [Abstract][Full Text] [Related]
3. CCN3/CCN2 regulation and the fibrosis of diabetic renal disease.
Riser BL; Najmabadi F; Perbal B; Rambow JA; Riser ML; Sukowski E; Yeger H; Riser SC; Peterson DR
J Cell Commun Signal; 2010 Mar; 4(1):39-50. PubMed ID: 20195391
[TBL] [Abstract][Full Text] [Related]
4. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.
Riser BL; Najmabadi F; Perbal B; Peterson DR; Rambow JA; Riser ML; Sukowski E; Yeger H; Riser SC
Am J Pathol; 2009 May; 174(5):1725-34. PubMed ID: 19359517
[TBL] [Abstract][Full Text] [Related]
5. Yin and Yang revisited: CCN3 as an anti-fibrotic therapeutic?
Leask A
J Cell Commun Signal; 2015 Mar; 9(1):97-8. PubMed ID: 25700690
[TBL] [Abstract][Full Text] [Related]
6. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
Krämer S; Wang-Rosenke Y; Scholl V; Binder E; Loof T; Khadzhynov D; Kawachi H; Shimizu F; Diekmann F; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F440-9. PubMed ID: 18094032
[TBL] [Abstract][Full Text] [Related]
7. Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2.
Leask A
J Cell Commun Signal; 2009 Jun; 3(2):161-2. PubMed ID: 19475498
[TBL] [Abstract][Full Text] [Related]
8. CCN3 suppresses TGF-β1-induced extracellular matrix accumulation in human mesangial cells in vitro.
Liu HF; Liu H; Lv LL; Ma KL; Wen Y; Chen L; Liu BC
Acta Pharmacol Sin; 2018 Feb; 39(2):222-229. PubMed ID: 28858296
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy.
Riser BL; Najmabadi F; Garchow K; Barnes JL; Peterson DR; Sukowski EJ
Am J Pathol; 2014 Nov; 184(11):2908-21. PubMed ID: 25193594
[TBL] [Abstract][Full Text] [Related]
10. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
[TBL] [Abstract][Full Text] [Related]
11. CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation.
van Roeyen CR; Eitner F; Scholl T; Boor P; Kunter U; Planque N; Gröne HJ; Bleau AM; Perbal B; Ostendorf T; Floege J
Kidney Int; 2008 Jan; 73(1):86-94. PubMed ID: 17914348
[TBL] [Abstract][Full Text] [Related]
12. Reduced NOV/CCN3 Expression Limits Inflammation and Interstitial Renal Fibrosis after Obstructive Nephropathy in Mice.
Marchal PO; Kavvadas P; Abed A; Kazazian C; Authier F; Koseki H; Hiraoka S; Boffa JJ; Martinerie C; Chadjichristos CE
PLoS One; 2015; 10(9):e0137876. PubMed ID: 26367310
[TBL] [Abstract][Full Text] [Related]
13. CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC.
Borkham-Kamphorst E; van Roeyen CR; Van de Leur E; Floege J; Weiskirchen R
J Cell Commun Signal; 2012 Mar; 6(1):11-25. PubMed ID: 21748432
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
15. C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis.
Wilkening A; Krappe J; Mühe AM; Lindenmeyer MT; Eltrich N; Luckow B; Vielhauer V
Nephrol Dial Transplant; 2020 Feb; 35(2):227-239. PubMed ID: 30597038
[TBL] [Abstract][Full Text] [Related]
16. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report.
Riser BL; Cortes P; DeNichilo M; Deshmukh PV; Chahal PS; Mohammed AK; Yee J; Kahkonen D
Kidney Int; 2003 Aug; 64(2):451-8. PubMed ID: 12846740
[TBL] [Abstract][Full Text] [Related]
17. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Krämer S; Kron S; Wang-Rosenke Y; Loof T; Khadzhynov D; Morgera S; Kawachi H; Shimizu F; Martini S; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F801-11. PubMed ID: 18216152
[TBL] [Abstract][Full Text] [Related]
19. Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family.
Abd El Kader T; Kubota S; Janune D; Nishida T; Hattori T; Aoyama E; Perbal B; Kuboki T; Takigawa M
J Cell Commun Signal; 2013 Mar; 7(1):11-8. PubMed ID: 23065484
[TBL] [Abstract][Full Text] [Related]
20. Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis.
Takahashi T; Abe H; Arai H; Matsubara T; Nagai K; Matsuura M; Iehara N; Yokode M; Nishikawa S; Kita T; Doi T
J Biol Chem; 2005 Feb; 280(8):7100-6. PubMed ID: 15591053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
